Navigation Links
NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution
Date:11/11/2011

LAWRENCE, Mass. and PHILADELPHIA, Nov. 11, 2011 /PRNewswire/ -- Booth # 407 at The American Society of Nephrology (ASN)'s Kidney Week 2011 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has won a multi-year contract to supply the Vasc-Alert™ Access Surveillance Solution to Atlantic Dialysis Management Services centers.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

"Robust access surveillance is increasingly important for outcomes, center economics, and compliance under the new bundled payment system.  We believe Vasc-Alert's patented, automated technology simplifies and demonstrably improves a provider's ability to be effective in this area," said Mark Florence, Vice President & General Manager at Medisystems, a NxStage Company. "This agreement builds on a successful partnership between NxStage and Atlantic and demonstrates how Atlantic employs innovative new technology to improve patient care."

"After a thorough evaluation of Vasc-Alert, we believe we can reduce our rate of thrombectomy with this product technology," said J. Ganesh Bhat, M.D., Co-Principal, Atlantic Dialysis Management Services, L.L.C. "Vasc-Alert helps advance our goal of reducing hospitalizations and catheter usage. In addition, it provides a simple and convenient way to comply with CMS requirements for access surveillance without increasing staff workload."

About Vasc-Alert

Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient's scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis -- a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.

About Atlantic Dialysis Management Services, L.L.C.

Atlantic Dialysis Management Services, L.L.C. was established to provide new dialysis site development, day to day administration and management of dialysis services and related business development activities. Atlantic Dialysis affiliates will provide over 250,000 dialysis treatments in 2011 to an estimated 2,500 patients in New York City and Long Island.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 20011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FREEDOM Data Adds to Compelling Evidence in Support of More Frequent Home Hemodialysis with NxStage System One
2. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
3. NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
4. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
5. NxStage Says Thank You to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans
6. NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill
7. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
8. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
9. NxStage to Present at UBS Global Life Sciences Conference
10. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
11. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):